# Foresite Capital

> Foresite Capital is a VC fund backing Biotechnology and Health Care. See 195 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 195
- Last investment: Jun 2026
- Lead investor: 31%
- Last fund: Jun 2024
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1451892
- X (Twitter): https://twitter.com/ForesiteCapital
- Website: http://www.foresitecapital.com

Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.

## Contacts

5 contacts available for Foresite Capital. Shizune tracks 8 team members at Foresite Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/foresite-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $22M–$165M |
| Series B | $25M–$140M |
| Series C | $38M–$270M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 99 | 51% |
| Health Care | 80 | 41% |
| Therapeutics | 41 | 21% |
| Medical | 37 | 19% |
| Life Science | 27 | 14% |

36 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 46 | 24% |
| Series C | 38 | 19% |
| Series A | 26 | 13% |
| Post-IPO Equity | 19 | 10% |
| Series D | 14 | 7% |

14 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 99 | 51% |
| United Kingdom | 6 | 3% |
| China | 2 | 1% |
| Australia | 2 | 1% |
| Canada | 1 | 1% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dorothy Margolskee | Managing Director | 1 | https://shizune.co/investors/profile/dorothy-margolskee |
| James Tananbaum | Founder and CEO | 25 | https://shizune.co/investors/profile/jim-tananbaum |
| Stephen C. Peterson | Partner | 1 | https://shizune.co/investors/profile/stephen-c-peterson |
| Dennis D. Ryan | CFO & Managing Director | 0 | https://shizune.co/investors/profile/dennis-d-ryan |
| Elizabeth Liz Canis | Senior Advisor | 3 | https://shizune.co/investors/profile/elizabeth-liz-canis |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stepful | Stepful is an online learning platform that provides training programs for entry-level healthcare careers such as medical assistant, pharmacy technician, dental assistant, and related roles. It delivers its courses through live, instructor-led virtual classes, interactive assignments, and structured exam preparation for nationally recognizedcertifications. The platform also includes in-person clinical or externship components arranged through partner healthcare providers to help students gain practical experience. Stepful supports learners with additional services such as career coaching, resume preparation, and job search assistance after certification. Overall, it is designed to help students transition into healthcare roles by combining online instruction with hands-on training and employment support. | $55M | Series C | Jun 08, 2026 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| GH Research | GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. | $117.5M | Post-IPO Equity | Apr 29, 2026 |  |
| OnKure Therapeutics | OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M | Post-IPO Equity | Mar 27, 2026 |  |
| Pinnacle Medicines | Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. | $89M | Series B | Mar 26, 2026 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $505M |  | Mar 02, 2026 |  |
| Slate Medicines | Slate Medicines is a biotechnology company that develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention. The company aims to revolutionize migraine prevention for patients seeking alternative solutions. | $130M | Series A | Feb 24, 2026 |  |
| Midi Health | Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $100M | Series D | Feb 03, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M | Series B | Dec 16, 2025 |  |

10 of 195 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 37 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 27 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 24 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 21 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 19 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 19 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Blockchain Founders Fund](https://shizune.co/investors/profile/blockchain-founders-fund) — VC Fund
- [Force Over Mass Capital](https://shizune.co/investors/profile/force-over-mass-capital) — VC Fund
- [NewBound Venture Capital](https://shizune.co/investors/profile/excelsior-financial-partners) — VC Fund

## Featured in investor lists
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [All Investors in Isle of Man](https://shizune.co/investors/investors-isle-of-man)
- [All VC Funds in Isle of Man](https://shizune.co/investors/vc-funds-isle-of-man)
- [Biotech Investors in Isle of Man](https://shizune.co/investors/biotech-investors-isle-of-man)

## FAQ

### What does Foresite Capital invest in?

Foresite Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 195 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Foresite Capital's check size?

Foresite Capital typically joins rounds of $22M–$165M at Series A, $25M–$140M at Series B and $38M–$270M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Foresite Capital participates in.

### How do I contact Foresite Capital?

Public channels for Foresite Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Foresite Capital?

The team at Foresite Capital includes Dorothy Margolskee (Managing Director), James Tananbaum (Founder and CEO) and Stephen C. Peterson (Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co